Precision Medicine-based Targeted Therapy and companion diagnostics

Next-generation Oncology Technology

Next-generation Oncology Technology

Our Offering

Intelligenix Advanced Diagnostics is a biopharma company developing molecular-based therapeutic compounds and companion diagnostic tests for personalized medicine.

Intelligenix Advanced Diagnostics has licensed patented technology that utilizes unique molecular signatures to detect and predict cancer development years earlier than current clinical tests. Utilizing Artificial Intelligenix (AI)-driven screening creates an "early warning system" for cancer surveillance of patients, whether they are healthy, at high risk of developing cancer, or being monitored during or after cancer therapy. By utilizing molecular techniques, we are also developing next-generation assays that provide valuable diagnostic information to detect, diagnose, evaluate, and determine the best course of treatment for the patient.

Intelligenix Advanced Diagnostics is also developing therapies that offer more of a cancer-specific therapeutic approach to treating malignancies such as prostate and breast cancer than what can be offered by competitive therapies. By harnessing the power of our precision medicine-based companion diagnostics, we have developed targeted therapeutics that are directed to cancer factors that are specific to the patient, thus increasing positive outcomes.

Lack of molecular test to determine cancer risk

No reliable cancer early detection test

Current one-size-fit-all treatment approach

Lack of a vaccine for Breast and Prostate cancers

We are developing tests for determining cancer risk and early detection.

Our Precision Medicine diagnostics help determine the best course of treatment.

We are developing targeted molecular-based therapeutics.

First-in-class cancer vaccine.

Our Offering